OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Raje on the Rationale for CAR T-Cell Therapy in Multiple Myeloma

June 29th 2020

Noopur Raje, MD, discusses the rationale for CAR T-cell therapy in multiple myeloma.

Dr. Mateos on the Significance of the CANOVA Trial in R/R t(11;14) Myeloma

June 29th 2020

María-Victoria Mateos, MD, PhD, discusses the significance of the ongoing phase 3 CANOVA trial, which is examining venetoclax in patients with relapsed/refractory t(11;14) multiple myeloma.

Dr. Sokolova on the Rationale for Systematic Germline Testing in Prostate Cancer

June 29th 2020

Alexandra Sokolova, MD, discusses the rationale for ​systematic germline testing in patients with metastatic prostate cancer.

Dr. Agarwal on Cohort 6 Results ​From the COSMIC-021 Trial in mCRPC

June 29th 2020

Neeraj Agarwal, MD, discusses the results from the cohort 6 analysis of the COSMIC-021 trial in patients with metastatic castration-resistant prostate cancer​.

Dr. Wang on the Efficacy of KTE-X19 in Low- and High-Risk R/R MCL

June 26th 2020

Michael Wang, MD, discusses the efficacy of KTE-X19 in low- and high-risk patients with relapsed/refractory mantle cell lymphoma as part of the phase 2 ZUMA-2 trial.

Dr. Costello on Determining Proper Dosing of Carfilzomib in Relapsed/Refractory Myeloma

June 26th 2020

Caitlin Costello, MD, discusses proper dosing of carfilzomib in relapsed/refractory multiple myeloma.

Dr. Chi on the Utility of Liquid Biopsy in Prostate Cancer

June 26th 2020

Kim Chi, MD, discusses the utility of liquid biopsy in prostate cancer.

Dr. Kelly on the Next Steps With Radium-223 and Niraparib in mCRPC

June 26th 2020

William K. Kelly, DO, discusses the next steps with the combination of radium-223 dichloride and niraparib in metastatic castration-resistant prostate cancer.

Dr. Richardson on the Next Steps With CC-92480 Research in Relapsed/Refractory Multiple Myeloma

June 26th 2020

Paul G. Richardson, MD, discusses the next steps ​with the investigational cereblon E3 ligase modulator agent CC-92480 research in ​relapsed/refractory multiple myeloma.

Dr. DiNardo on the Rationale for the Pooled Analysis Evaluating Venetoclax in AML

June 26th 2020

Courtney DiNardo, MD, MSCE, discusses the rational​e for a pooled analysis evaluating venetoclax in acute myeloid leukemia.

Dr. Saad on Unique Characteristics of Apalutamide in M0CRPC

June 26th 2020

Fred Saad, MD, FRCS, discusses unique characteristics of apalutamide compared with other antiandrogen agents in nonmetastatic castration-resistant prostate cancer.

Dr. Sharman on ​the Challenges of Adjust​ing Treatment Based on MRD Status in CLL

June 26th 2020

Jeff P. Sharman, MD, discusses the challenges of adjusting treatments based on minimal residual disease status in high-risk chronic lymphocytic leukemia.

Dr. Kuruvilla on the Safety of Pembrolizumab in Classical Hodgkin Lymphoma

June 25th 2020

John Kuruvilla, MD, FRCPC, discusses the safety of pembrolizumab (Keytruda) versus brentuximab vedotin in classical Hodgkin lymphoma.

Dr. Berdeja on Next Steps With JNJ-4528 in Relapsed/Refractory Myeloma

June 25th 2020

Jesus G. Berdeja, MD, discusses next steps for the phase 2 CARTITUDE-1 study with JNJ-4528 in relapsed/refractory myeloma.

Dr. McKay on the Design of the PDIGREE Trial in Advanced RCC

June 25th 2020

Rana R. McKay, MD, discusses the design of the phase 3 PDIGREE study in advanced renal cell carcinoma.

Dr. Ramos on the Role of BCG In Non-Muscle Invasive Bladder Cancer

June 25th 2020

Félix Guerrero-Ramos, MD, PhD, FEBU, discusses the role of Bacillus Calmette-Guerin in the treatment of patients with non-muscle invasive bladder cancer.

Dr. Tykodi on the Efficacy of Dual Checkpoint Blockade in RCC

June 25th 2020

Scott S. Tykodi, MD, PhD, discusses the efficacy of dual checkpoint blockade in renal cell carcinoma.

Dr. Karmali on Optimizing Maintenance Therapy in Older Patients With MCL

June 24th 2020

Reem Karmali, MD, MS, discusses next steps for optimizing maintenance therapy in older patients with mantle cell lymphoma.

Dr. Jain on Future Research Efforts Examining Venetoclax Resistance Patterns in MCL

June 24th 2020

Preetesh Jain, MD, PhD, discusses research efforts examining resistance patterns with venetoclax in mantle cell lymphoma.

Dr. Moyers on Real-World Data With Adjuvant Immunotherapy in Melanoma

June 24th 2020

Justin Moyers, MD, discusses real-world data and sociodemographic factors from an early analysis of the National Cancer Database associated with the treatment of adjuvant immunotherapy in stage III melanoma.

NEXT PAGE
PREVIOUS PAGE